The fight over an experimental treatment for Alzheimer’s disease from Cassava Sciences likely won’t be resolved for years.
That’s the only certain takeaway from Thursday’s decision by the Food and Drug Administration to deny — on a technicality — several citizen petitions against Cassava and its drug, called simufilam. Investors who are long and short Cassava’s stock will now wait three years or more until two, recently started Phase 3 studies are completed and the results read out.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
